CNS Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. The company is a clinical-stage pharmaceutical developer focused on cancer candidates for brain and central nervous system tumors. It reported no revenue.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| R&D expense | $2.85 million | $2.22 million | $6.41 million | $4.11 million |
| General and administrative expense | $1.18 million | $1.34 million | $2.54 million | $2.60 million |
| Total operating expenses | $4.03 million | $3.56 million | $8.95 million | $6.71 million |
| Net loss | $4.02 million | $3.57 million | $8.95 million | $6.72 million |
| Basic and diluted loss per share | $1.04 | $2.67 | $3.10 | $5.11 |
- Six-month R&D expense rose about 56%; management attributed the increase primarily to Berubicin clinical-trial CRO costs. Six-month net loss increased about 33%. In Q2, R&D rose about 28%, while G&A declined about 12%.
- Six-month operating cash use was $8.23 million, versus $6.44 million a year earlier. Financing provided $2.45 million, versus $10.40 million, mainly from common-stock sales and warrant exercises.
- Cash and cash equivalents were $4.28 million at June 30, down from $10.06 million at December 31, 2022. Working capital was approximately $2.07 million. Current assets were $6.07 million and current liabilities $4.00 million.
- Notes payable were $166,396, down from $409,968 at year-end; the remaining short-term note was due by October 31, 2023. The filing provides no clear gross-margin measure; with no revenue reported, operating margins are not meaningful.
Business developments, outlook and risks
- Berubicin is the company’s lead candidate. Its randomized Phase II study for recurrent glioblastoma compares Berubicin with lomustine and targets approximately 243 patients. Management anticipated a non-binding interim futility analysis and potential data release in Q4 2023; enrollment, timing and results remain uncertain.
- Management expected cash to fund planned operations into, but not beyond, Q4 2023. It estimated a further $9.1–$13.1 million would be needed to complete the Berubicin trial, plus approximately $5.0 million for near-term WP1244/WP1874 preclinical work and additional operating working capital. The company stated it must raise additional capital and that failure to do so could require extending payables, cutting overhead or scaling back plans.
- The filing states that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Management said cash on hand was sufficient only into the near term and that financing plans may not be achievable.
- The company raised $1.97 million net from common-stock sales and received $726,000 from warrant exercises during the six months. It had an at-the-market sales agreement allowing up to $20 million in aggregate sales; after quarter-end, it sold 58,591 shares for $124,279 net. These financings and warrant exercises increase potential dilution.
- UTMDACC may terminate the WP1244 license because the company had not met specified commercial diligence milestones; as of the report date, UTMDACC had not given notice of termination. The company also depends on third parties for manufacturing and clinical-trial operations.
- Disclosure controls were deemed ineffective due to material weaknesses, including insufficient segregation of duties, delays and gaps in CRO cost information, and inadequate formal control documentation. Management described remediation efforts, but noted segregation-of-duties limitations remain.
- The company reported no current legal proceedings. It also disclosed a $550,750 cash bonus award to officers approved in March 2023.
Most important facts for investors to verify
- Actual cash runway, subsequent financing, dilution and the amount and terms of capital required to fund operations and complete the Berubicin trial.
- Berubicin trial enrollment, interim-analysis timing and findings, and whether the study remains on plan.
- Whether UTMDACC exercises its termination right over the WP1244 license and the status of related development plans.
- Progress in remediating internal-control weaknesses and improving access to complete, timely CRO cost data.
- Outstanding note repayment, accrued obligations and any material changes in clinical-trial costs or other commitments.